Why Is NRX Pharmaceuticals (NRXP) Stock Down 23% Today?


  • NRX Pharmaceuticals (NRXP) stock is down on public offering plans.
  • The company hasn’t revealed the price or size of the offering yet.
  • However, it has laid out plans for the funds from the offering.
NRXP Stock - Why Is NRX Pharmaceuticals (NRXP) Stock Down 23% Today?

Source: Shutterstock

NRX Pharmaceuticals (NASDAQ:NRXP) stock is falling on Tuesday after the clinical-stage pharmaceutical company announced a proposed public offering for its shares.

We still don’t know the finer details of the public offering. That’s due to NRX Pharmaceuticals not yet setting a price for the shares or saying how many of them will be included in the underwritten public offering.

What we do know is that EF Hutton LLC is serving as the sole book-running manager for the public offering. NRX Pharmaceuticals also says that all shares sold in the offering will come directly from it.

Other details we know are the company’s plans for the net proceeds from the offering. It intends to use the money for working capital and general corporate purposes. NRX Pharmaceuticals may also use the funds to repay some of its outstanding debts.

What a Public Offering Means for NRXP Stock

This public offering would increase the total number of outstanding NRXP shares. That will also dilute the stakes of current shareholders. This is one of the reasons the stock is falling today.

Another concern is the price of the offering. While one hasn’t been announced yet, shares in public offerings are also normally discounted. That’s another likely reason for today’s NRXP decline.

NRXP stock is down 22.8% as of Tuesday morning.

Investors looking for all of the latest stock market stories are in luck!

We have all of the hottest market coverage traders need to know about on Tuesday! That includes everything happening with Aaron’s (NYSE:AAN) stock, Rivian Automotive (NASDAQ:RIVN) stock and Infobird (NASDAQ:IFBD) stock this morning. All of that news is ready to go at the links below!

More Stock Market News for Tuesday

On Penny Stocks and Low-Volume Stocks: With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That’s because these “penny stocks” are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that InvestorPlace.com’s writers disclose this fact and warn readers of the risks. 

Read More: Penny Stocks — How to Profit Without Getting Scammed 

On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.

Article printed from InvestorPlace Media, https://investorplace.com/2024/02/why-is-nrx-pharmaceuticals-nrxp-stock-down-23-today/.

©2024 InvestorPlace Media, LLC